Schizophrenia and osteoporosis

被引:20
作者
Lean, M [1 ]
De Smedt, G
机构
[1] Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland
[2] Tibotec Virco NV, Mechelen, Belgium
关键词
antipsychotic; osteoporosis; prolactin; schizophrenia;
D O I
10.1097/00004850-200401000-00006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although it has been suggested that antipsychotic-induced hyperprolactinaemia in schizophrenic patients may lead to an increased risk of osteoporosis, this has not been proven. Osteoporosis is a multifactorial disease, and untreated patients with schizophrenia are at risk due to both the consequences of the disease and related lifestyle factors. Evidence from available studies does not show that anti psychotic-induced hyperprolactinaemia is an independent risk factor for osteoporosis in schizophrenic patients. Osteoporosis would be expected in women who develop amenorrhoea as a result of hyperprolactinaernia secondary to antipsychotics, but there is no plausible mechanism in men. The uncertainty over this issue underlines the need for full medical and metabolic assessment and monitoring of psychiatric patients. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 28 条
[1]   OSTEOPOROSIS AND SCHIZOPHRENIA - CAN WE LIMIT KNOWN RISK-FACTORS [J].
ABRAHAM, G ;
FRIEDMAN, RH ;
VERGHESE, C ;
DELEON, J .
BIOLOGICAL PSYCHIATRY, 1995, 38 (02) :131-132
[2]   Prolactin elevation with quetiapine [J].
Alexiadis, M ;
Whitehorn, D ;
Woodley, H ;
Kopala, L .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (09) :1608-1609
[3]  
ATAYA K, 1988, FERTIL STERIL, V50, P876
[4]   Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia [J].
Bilici, M ;
Cakirbay, H ;
Guler, M ;
Tosun, M ;
Ulgen, M ;
Tan, U .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2002, 112 (07) :817-828
[5]  
Breier AF, 1999, AM J PSYCHIAT, V156, P294
[6]   Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder [J].
Chou, JCY ;
Douyon, R ;
Czobor, P ;
Volavka, J ;
Cooper, TB .
PSYCHIATRY RESEARCH, 1998, 81 (01) :51-55
[7]  
Cohen HJ, 2000, FOOD CHEM TOXICOL, V38, P237
[8]  
De Smedt G, 2002, EUR NEUROPSYCHOPHARM, V12, pS301
[9]   Neuroleptic-induced hyperprolactinemia [J].
Dickson, RA ;
Glazer, WM .
SCHIZOPHRENIA RESEARCH, 1999, 35 :S75-S86
[10]  
Francis RM, 1999, CLIN ENDOCRINOL, V50, P411